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Topographical Mapping of Epitopes on the Glycoproteins of Murine 
Hepatitis Virus-4 (Strain JHM): Correlation with Biological Activities 
PIERRE J. TALBOT, AIM0 A. SALMI: ROBERT L. KNOBLER, 
AND MICHAEL J. BUCHMEIER’ 
Department of Immunology, Scripps Clinic and Research Foundation, La Jolla, Cal$bka 920.97 
Received May 20, 1988; accepted October 22, 1983 
Monoclonal hybridoma antibodies (MAb) of defined polypeptide specificity and biological 
activity were used in a competition binding assay to identify antibody binding sites 
(epitopes) on the glycoproteins of murine hepatitis virus-4 strain JHM (MHV-4). Individual 
MAb were labeled with horseradish peroxidase (HRP) and used as probes in a competition 
enzyme immunoassay (EIA). Four topographically distinct antigenic sites were detected 
on the E2 glycoprotein of MHV-4. Antibodies reacting with these four determinants 
provisionally designated A(E2), B(E2), C(E2), and D(E2) had corresponding biological 
activities (M. J. Buchmeier, H. A. Lewicki, P. J. Talbot, and R. L. Knobler (1984) Vi’irology 
132,261-270). Antibodies to sites A(E2) and B(E2) mediated virus neutralization in vitro 
and passively protected mice against lethal virus challenge in viva. Antibody to site C(E2) 
neutralized virus efficiently in vitro but did not alter disease in viwo, while antibody to 
site D(E2) neither neutralized nor protected. Two major nonoverlapping antigenic sites 
were defined on the El glycoprotein. Overlapping epitopes A(E1) and B(E1) constituted 
one site and epitope C(E1) the other. 
INTRODUCTION 
The JHM strain of MHV-4 is a neuro- 
tropic member of the Coronaviridae (Tyr- 
rell et al, 1975). Under appropriate con- 
ditions or by the use of attenuated tem- 
perature sensitive mutants of MHV-4, 
demyelination results (Weiner, 1973; Stohl- 
man and Weiner, 1981; Knobler et aL, 1981, 
1982) which has been investigated for par- 
allels with human demyelinating disorders 
of unknown etiology (Maugh, 1977). Studies 
have shown that demyelination during 
MHV-4 infection is a direct effect of virus 
infection of the oligodendrocyte (Weiner, 
1973; Lampert et al, 1973; Knobler et aL, 
1982), an effect normally masked during 
acute infection when neuronal infection 
results in fulminant encephalomyelitis 
i On sabbatical leave from the Department of Vi- 
rology, University of Turku, Finland. 
2 To whom correspondence and requests for reprints 
should be addressed at Department of Immunology 
(IMMG), Scripps Clinic and Research Foundation, 
10666 North Torrey Pines Road, La Jolla, Calif. 92037. 
(Weiner, 1973; Stohlman and Weiner, 1981). 
Despite elegant morphological studies 
from several laboratories (Weiner, 1973; 
Lampert et al, 1973; Nagashima et al, 1978; 
Sorensen et ah, 1980; Knobler et cd, 1982), 
detailed understanding of the factors 
which influence virus-induced demyelina- 
tion is still lacking. 
The MHV virion contains a helical nu- 
cleocapsid composed of a 5.4-6.9 X 10” 
relative molecular weight (ilf,) single- 
stranded, message sense RNA and a 50-63 
K (M, X 10p3) nucleocapsid (N) protein 
(Siddell et a& 1982; Sturman and Holmes, 
1983). In addition to the N protein, the vi- 
rion contains two glycoproteins termed El 
and E2 by Sturman and Holmes (1977). A 
structural model for the incorporation of 
El and E2 into MHV virions has recently 
been proposed (Sturman et a& 1980; Stur- 
man and Holmes, 1983). The large glyco- 
protein E2 is associated with the virion 
peplomers, contains N-linked oligosaccha- 
rides, and is composed of at least two re- 
lated polypeptides: 150-200K and 90-100K 
(Sturman and Holmes, 1977; Wege et al, 
0042-6822184 $3.00 
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1979; Bond et or, 1979; Siddell, 1982). An 
intracellular 150K glycosylated precursor 
polypeptide has been described (Siddell et 
al, 1981; Siddell, 1982) with an apoprotein 
of llO-120K (Rottier et a& 1981). The El 
glycoprotein contains O-linked oligosac- 
charides (Niemann and Klenk, 1981; 
Holmes et al, 1981) and appears to be 
embedded in the membrane. Available ev- 
idence suggests that El interacts with the 
internal N protein (Sturman et a& 1980). 
In the virions, both glycosylated 23-26K 
and nonglycosylated 18-23K forms of the 
El protein exist (Wege et c& 1979; Siddell 
et al, 1981; Rottier et a& 1981). 
Monoclonal antibodies (MAb) were gen- 
erated in this laboratory against the 
structural proteins of MHV-4. These MAb 
were used in previous studies to assign the 
attachment and fusion activities of the vi- 
rus to the glycoprotein E2 (Collins et al, 
1982). In order to more precisely define the 
structure of the El and E2 glycoproteins, 
we have performed competition enzyme 
immunoassays to define epitopes associated 
with previously described biological activ- 
ities of the MHV-4 glycoproteins. 
MATERIALS AND METHODS 
Virus and cell culture. Murine hepatitis 
virus-4 was originally obtained from Dr. 
Leslie P. Weiner (Collins et aL, 1982) and 
is routinely propagated and assayed in this 
laboratory on L-24 cells as previously de- 
scribed (Collins et aL, 1982). Cells were in- 
fected with MHV-4 (m.o.i. = 0.01-l) and 
incubated until extensive syncytium for- 
mation was observed (15-20 hr) to serve 
as a source of viral antigen for immuno- 
blotting and EIA assays described below. 
Monoclom~l antibodies to MHV-4. The 
generation and characterization of MAb to 
MHV-4 structural proteins were described 
previously (Collins et uL, 1982). Virus neu- 
tralization assays and passive protection 
studies were performed as described 
(Buchmeier et aL, 1984). 
Western immunoblotting. In addition to 
immunoprecipitation (Collins et aL, 1982), 
specificity of our MAb was defined by 
Western immunoblotting (Towbin et aL, 
1979). For this technique, cytosol extracts 
of infected and control uninfected L-24 
cells were prepared by a modification of a 
previously described method (Collins 
et aL, 1982). Infected and control cultures 
(2 X 10’ cells) were washed with rinse 
buffer (20 mM Tris-HCl, pH 9.0; 137 mM 
NaCl; 1 mM CaClz, and 0.5 mM MgClz) and 
solubilized for 20 min in 3-ml ice-cold lysis 
buffer (rinse buffer with 1% (v/v) Nonidet- 
P40; 10% (v/v) glycerol, and 1% (v/v) apro- 
tinin). Cell debris was pelleted at 1000 g 
for 10 min and cytosols were obtained after 
centrifugation at 100,000 Q for 60 min. Pro- 
teins were separated by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) on 10.5% acrylamide sepa- 
rating gels (Laemmli, 1970). Nitrocellulose 
replicas were prepared by electrophoretic 
transfer for 6 hr at 5 V/cm as previously 
described (Erickson et aL, 1982). Quanti- 
tative transfer of even high molecular 
weight (>150K) proteins was achieved. 
Following transfer, nitrocellulose was 
saturated by incubation for 60 min with 
3% (w/v) bovine serum albumin in PBS 
with 0.5% (v/v) Nonidet-P40, 0.1% (w/v) 
sodium deoxycholate, and 1% (v/v) normal 
goat serum. Strips were incubated for 3 hr 
at 37” with hybridoma cell supernatants 
diluted fourfold with the same buffer, then 
washed three times in PBS + 0.05% (v/v) 
Tween 20. Bound antibodies were detected 
by incubation for 1 hr with ‘%I-labeled, 
affinity-purified goat antibody to mouse Ig 
(Buchmeier et CAL, 1981; sp act 3-5 &i/pg; 
lo6 cpm per gel lane). The strips were again 
washed, dried, and autoradiographed. 
Coupling of horseradish peroxidase 
(HRP) to mono&ma1 antibodies. Immuno- 
globulin fractions were isolated from as- 
cites fluids by precipitation at 4’ with an 
equal volume of saturated ammonium sul- 
fate (pH 7.0). After overnight dialysis 
against three changes of 0.01 M sodium 
carbonate buffer, pH 9.5, immunoglobulin 
(Ig) concentrations were estimated by ra- 
dial immunodiffusion against goat anti- 
mouse IgG (Meloy Laboratories, Spring- 
field, Va.). Antibodies were coupled to HRP 
(Sigma, St. Louis, MO.) by the periodate 
method (Wilson and Nakane, 1978) and 
stored in an equal volume of glycerol at 
-70”. This technique has previously been 
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shown to covalently couple an average of 
one enzyme molecule per immunoglobulin 
via secondary amino groups (Wilson and 
Nakane, 1978). 
Enzyme immunoassays (EIA). The solid- 
phase immunoassay principle employing 
microtiter plates was used throughout. 
Preliminary studies (Talbot and Salmi, 
unpublished, 1983) showed that certain 
subcellular fractions from infected cells 
could be used as antigens on solid phase. 
A particulate fraction was prepared from 
uninfected and MHV-binfected cells as 
follows. Cells were scraped off the flasks, 
washed three times with cold Dulbecco’s 
phosphate buffer saline, pH 7.4 (PBS), and 
resuspended in the same buffer (4 X lo7 
cells/ml). Cell suspensions were disrupted 
by five cycles of rapid freezing and thawing 
followed by two 1-min cycles of sonication 
on ice slurry with a Microtip at a 
maximum energy in a probe-type sonicator 
(Heat Systems-Ultrasonics, Inc., Plain- 
view, N. Y.). Cellular debris was removed 
by centrifugation at 1000 g for 10 min and 
particulate material pelleted at 100,000 g 
for 60 min. Pellets were resuspended in 
PBS and sonicated as above. Protein con- 
centration was determined (Lowry et al, 
1951) using bovine serum albumin as a 
standard. Antigens were stored at 4’ in 
the presence of 0.5 mM merthiolate. 
Microtiter plates (Linbro Titertek, Flow 
Laboratories, Cat. No. 76-202-05) were 
coated with 0.1 ml/well of viral or control 
antigens with total protein concentration 
of 5 pg/ml. After overnight antigen coating 
at room temperature, free binding sites of 
the polystyrene wells were blocked with 
0.15 ml/well of EIA diluent (PBS supple- 
mented with 10% (v/v) heat-inactivated 
fetal calf serum, 0.2% (v/v) Tween 20, and 
0.5 mM merthiolate). After an incubation 
of at least 1 hr at room temperature, an- 
tigen-coated plates were used for antibody 
binding or for competition binding assays. 
In antibody binding assays, serial two- 
fold dilutions of monoclonal antibodies as 
ascites fluids were incubated in antigen- 
coated plates for 75 to 90 min at room tem- 
perature which was the incubation tem- 
perature in all the subsequent steps as well. 
The plates were washed three times with 
a washing solution (PBS supplemented 
with 0.05% (v/v) Tween 20) and HRP-la- 
beled affinity-purified antibodies to mouse 
IgG and IgM (Boehringer-Mannheim Bio- 
chemicals, Indianapolis, Ind.) were added. 
After 75 to 90 min incubation, the plates 
were washed as above and 0.1 ml of the 
substrate solution consisting of 3 mM hy- 
drogen peroxide and 2.2 mM o-phenylene- 
diamine in 0.1 Msodium citrate buffer, pH 
5.0 was added into each well. The enzyme 
reaction was terminated after 30 min in- 
cubation in subdued light by adding 0.1 ml 
of 1 NHCl into each well. Optical densities 
were read (OD,,) with a Titertek Multi- 
skan photometer (manufactured by Eflab, 
Helsinki, Finland). 
The competition binding assays were 
performed as above with the following 
modifications. After 75 to 90 min incuba- 
tion of fourfold dilutions of the ascites 
samples containing different MAb, only one 
gentle washing cycle was performed. A 
previously determined optimal amount of 
HRP-conjugated MAb to MHV-4 was 
added to the plates in volumes of 0.1 ml/ 
well. After 75 to 90 min incubation, plates 
were washed three times, substrate added, 
and ODdg2 read as above. Since the non- 
specific binding of individual conjugates 
varied considerably, binding to control an- 
tigen was taken to represent background, 
and binding of each conjugate to viral an- 
tigen as maximum binding. This difference 
was taken to represent 100% binding, and 
the relative inhibition by the competing 
first antibody was normalized to this scale 
in each individual test. 
RESULTS 
Polypeptide specificity of mono&ma1 an- 
tibodies to MHV.4. The polypeptide speci- 
ficity of monoclonal antibodies against 
MHV-4 was initially characterized by im- 
munoprecipitation of radiolabeled viral 
proteins from infected cell extracts (Collins 
et a& 1982). While specificities could be as- 
signed based upon the predominant poly- 
peptide in immunoprecipitates, coprecip- 
itation of other viral polypeptides was oc- 
casionally observed. These ambiguities 
were eliminated by the immunoblotting 
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technique, as illustrated in Fig. 1A. Mono- 
clonal antibodies to the E2 glycoprotein 
reacted with virus-specific polypeptides 
migrating at approximately 100, 160, and 
230K, as well as with high molecular 
weight aggregates which did not penetrate 
separating gels (Wege et aL, 1979; Siddell 
et aL, 1981). Antibodies to the glycoprotein 
El reacted only with a doublet of 25 and 
23K. Nucleocapsid protein antibodies re- 
acted only with a 56K protein. The sum- 
marized results of immunoblotting anal- 
yses and the corresponding biological 
properties are shown in Table 1. Six of 
thirteen antibodies to MHV-4 glycopro- 
teins El and E2 were unable to bind to 
denatured viral polypeptides blotted to ni- 
trocellulose whereas all of five antibodies 
to N bound well to the denatured molecule. 
For these antibodies which did not react 
on Western immunoblots, the previously 
described (Collins et ab, 1982) immuno- 
precipitation technique was used (Fig. 1B). 
Four of eight antibodies to E2 neutral- 
ized virus infectivity in vitro, recapitulat- 
ing previous results (Collins et al, 1982). 
With one exception (antibody 4B11.6), the 
neutralizing antibodies were found in sep- 
arate studies to be protective upon passive 
transfer to mice prior to or concurrent with 
intracerebral virus challenge (Buchmeier 
et al, 1984). 
Enzp,w immunoassay of MAb to MHV-4 
glycoproteim. Comparative studies indi- 
cated that a membrane-enriched fraction 
prepared from virus-infected cells provided 
the optimal antigen source and that all 
antibodies showed binding characteristics 
to the antigen preparation equivalent to 
their binding to purified virions (Talbot and 
Salmi, unpublished, 1983). The minimum 
antigen concentration (0.5 pg total protein 
per well) which provided maximum anti- 
body binding with all of the three classes 
of antibodies examined was selected and 
used throughout this study (Fig. 2). Bind- 
ing characteristics of MAb to MHV-4 gly- 
coproteins were determined by parallel 
solid-phase EIA titrations using a single 
antigen preparation. Binding curves of 
A- Western lmmunoblotting B- lmmunopracipitation 
MHV 
5819.2 5A5.2 486.2 Cvtosol 5B119.4 
205;: 
116k- 
94k- 
67k- 
30k- -‘“* 
E2- 
N- 
El- 
20k- 
I c I c I c 
Cytosol Preparation 
FIG. 1. Polypeptide specificities of MHV-4 monoclonal antibodies. Antibodies were reacted by 
Western immunoblotting (Fig. 1A) on nitrocellulose replica of SDS-PAGE-separated polypeptides 
from infected (I) or control (C) cytosol preparations of L-24 cells, as described in the text. Migration 
positions of molecular weight markers are shown on the left, as well as the origin of the separating 
gel (0). Monoclonal antibodies and their polypeptide reactivities were 5B19.2 (anti-E2: 100, 160, 
230K, and high molecular weight aggregates at the origin), 5A5.2 (anti-El: 23K, 25K) and 4B6.2 
(anti-N: 56K). Immune precipitation of viral polypeptides from cytosol of MHV4-infected L-24 cells 
by monoclonal antibodies (Fig. 1B). Cells were infected with MHV-4, then pulse-labeled with 
[%]methionine and a cytosol extract prepared and immunoprecipitated with antibody 5B119.4 
specific for the El polypeptides 23 and 25K. 
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TABLE 1 
SUMMARYOFCHARA~TERISTICSOFMONOCLONALANTIBODIESTO MHV-4 
Hybridoma 
designation 
It?” 
subclass 
Polypeptide 
specificity 
Reaction in 
Western 
immunoblotting” 
In vitro 
neutralization” 
In viva 
protectiond 
5B19.2 IgGl E2 + + + 
5B170.3 IgGl + + + 
5A13.5 IgG2A - + + 
4B11.6 IgG2A - + - 
5B21.5 IgGl + - - 
5B93.9 Id + - 
- 
5B207.7 IgG2B + - - 
5B216.8 IgG2A - - - 
5B11.5 IgG2A 
5A5.2 IgG3 
5B119.4 IgG2A 
5B128.3 IgG3 
5B39.1 IgG3 
4B6.2 IgGl 
5B145.5 I& 
5B175.6 IgG2A 
5B86.2 IgG3 
5B188.2 IgG2A 
- 
+ 
- 
+ 
- 
+ 
+ 
+ 
+ 
+ 
- 
- 
- 
- 
- 
- 
nd 
- 
nd 
nd 
- 
- 
- 
nd” 
nd 
- 
nd 
nd 
nd 
nd 
’ Abbreviations: Ig, immunoglobulin; nd, not done. 
* Binding of monoclonal antibody on nitrocellulose replica of SDS-PAGE-separated polypeptides. 
’ +: 50% plaque reduction at ascites dilution of more than 1:lOOO (Buchmeier et aL, 1984). 
d +: >80% mice protected from lethal virus challenge (Buchmeier et aL, 1984). 
typical antibodies are presented in Fig. 3. 
Most antibodies appeared to bind with high 
avidity to the viral glycoproteins since the 
maximal level of measurable binding was 
reached (Frankel and Gerhard, 1979; Stone 
and Nowinski, 1980; Massey and Schoch- 
etman, 1981). 
Molecular topography of epitopes on 
MHV-4 glycoproteins by competitim bind- 
ing EIA. Our initial attempts to define 
the topography of antigenic sites on the 
MHV-4 glycoproteins made use of conven- 
tional solid-phase competitive radioim- 
munoassay with radioiodinated MAb. 
However, the binding efficiencies of many 
of the purified MAb were diminished fol- 
lowing radiolabeling. On the other hand, 
most of our MAb retained their binding 
properties when conjugated to peroxidase 
(Wilson and Nakane, 19’78), thus allowing 
the use of a sensitive enzyme-linked im- 
munoassay format. Monoclonal antibodies 
to MHV-4 described in Table 1 (except 
5B86.2 and 5B188.2, which were not yet 
available in the form of ascites fluids) were 
conjugated to HRP. Several dilutions of 
these HRP conjugates were titrated by EIA 
on antigens prepared from infected and 
control cells, as described under Materials 
and Methods, and for each conjugate, three 
dilutions representing approximately 90, 
50, and 30% saturation of viral antigen 
were selected. Binding inhibition by non- 
conjugated homologous and heterologous 
antibodies was titrated against each of the 
three conjugate dilutions to determine the 
most sensitive experimental conditions. 
The results of typical competition bind- 
ing assays are presented in Figs. 4 and 5 
and the data summarized in Table 2. Bind- 
ing of HRP-conjugated MAb was inhibited 
from 70 to 99% in the presence of excess 
unlabeled homologous antibody. Variation 
observed related to the quality of HRP 
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Total Protein Ipgfwelll 
FIG. 2. Specific binding of monoclonal antibodies to 
a membrane-enriched fraction of MHV-4 infected 
cells. Various quantities of membrane-enriched frac- 
tion from MHV-4 infected or control L-24 cells were 
adsorbed in the wells of microtiter plates. Previously 
determined optimal dilutions of monoclonal ascites 
fluids against viral protein E2, El, or N were bound 
and detected with HRP-labeled goat anti-mouse Ig, 
as described in the text. Specific binding was expressed 
as OD,, (virus antigen)-OD,% (control antigen). 
conjugates obtained for each MAb. Con- 
jugates with lower EIA titers were added 
at higher concentration and their binding 
could be inhibited to a lesser extent by un- 
conjugated homologous antibodies, thus 
decreasing the sensitivity of the assay. For 
that reason, some conjugates did not pro- 
vide reliable probes in competition binding 
assays. Nevertheless, all the available an- 
tibodies were tested as unconjugated com- 
peting antibodies. Figure 4D shows the 
absence of nonspecific blocking in our 
competition binding assay since none 
of the glycoprotein antibodies inhibited the 
binding of an antibody probe to the N pro- 
tein. 
Two major antigenic regions could be 
distinguished on the small glycopro- 
tein El (Fig. 4). One site, designated C(El), 
was defined by the monoclonal antibody 
5B128.3. None of the other MAb tested 
(five against El, eight against E2, and 
three against N) blocked the binding of the 
probe; only homologous inhibition was ob- 
served (Fig. 4C). Another site was defined 
by El antibodies 5B119.4, 5A5.2, and 
5B11.5, which showed intermediate levels 
of reciprocal competition (Figs. 4A and B). 
This intermediate blocking could indicate 
structurally close and possibly overlapping 
epitopes which generated mutual incom- 
plete steric hindrance upon antibody bind- 
ing. Hence, we assigned epitope A(E1) to 
the MAb 5B119.4 and epitope B(E1) to 
5A5.2 to stress this uncertainty. The target 
epitope of 5B11.5 could not be precisely as- 
signed since reliable HRP-conjugated 
probes of this antibody were not obtained 
and inhibition of both 5B119.4 and 5A5.2 
conjugates was observed. 
Four antigenic sites could be assigned 
to the large glycoprotein E2 (Fig. 5). Site 
A(E2) was defined by two antibodies, 
5B19.2 and 5B170.3, which could compete 
with each other for binding to the viral 
o-El 
2.0 
1.0 
0.5 
K 
_-_-___-- ---- 
0.001 0.01 0.1 1 10 100 
pg lmmunoglobulin 
FIG. 3. Binding characteristics of different repre- 
sentative monoclonal antibodies to glycoproteins El 
(A) and E2 (B). Serial twofold dilutions of antibody 
in the form of ascites fluid were incubated in the wells 
of microtiter plates containing adsorbed membrane- 
enriched fraction from MHV-4 infected (-) or con- 
trol (- - -) L-24 cells. Control curves were obtained 
for each antibody and showed minimal deviations 
from the mean curve shown here. Bound antibodies 
were detected with HRP-labeled goat anti-mouse Ig, 
as described in the text. Immunoglobulin concentra- 
tion (pg) represents the total amount of unconjugated 
antibodies added. 
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60 
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7 
HAP5i52 lo-El1 
HRP486.2 bNI 
. 
0.001 0.01 0.1 1 5 0.001 0.01 0.1 1 
pg lmmunoglobulin 
6. 
A 
D 
5 
FIG. 4. Competition binding EIA with HRP-con- 
jugated monoclonal antibodies directed against gly- 
coprotein El (A-C) and nucleocapsid protein N (D). 
Serial fourfold dilutions of unconjugated antibodies 
in the form of ascites fluids were allowed to react 
with the antigen-coated plate. Unbound antibodies 
were removed and the binding of a previously deter- 
mined limiting amount of HRP-conjugated mono- 
clonal antibody probe was observed. The extent of 
blocking by unconjugated antibodies of conjugated 
probe binding was calculated as described in the text 
and expressed as percent competition. Immunoglob- 
ulin concentration (pg) represents the total amount 
of unconjugated antibodies added. Enzyme-conjugated 
antibodies directed against El were 5B119.4 (A), 585.2 
(B), and 5B128.3 (C). Antibody 4B6.2 (D) is directed 
against the N protein. 0,5B11.5; V, 5B119.4; A, 5A5.2; 
q I, 5B128.3; X, 4B6.2; .,5B19.2; V, 5B170.3; A, 5A13.5; 
W, 4B11.6. 
glycoprotein (Figs. 5A and B). Sites B and 
C(E2) were respectively defined by anti- 
bodies 5A13.5 and 4B11.6 and only homol- 
ogous blocking was observed at those an- 
tigenic determinants (Figs. 5C and D). Site 
D(E2) was defined by the four nonneu- 
tralizing antibodies which could not com- 
pete for antibody binding at sites A, B, or 
C(E2) (data not shown). 
DISCUSSION 
In this study, 13 monoclonal antibodies 
directed against the structural glycopro- 
teins of MHV-4 were used in competition 
binding immunoassays to identify anti- 
genie regions on these glycopeptides (Yew- 
dell and Gerhard, 1981). Based on our data 
and biological activities of the monoclonal 
antibodies studied, we were able to asso- 
ciate specific properties to these epitopes. 
Three nonoverlapping antigenic sites des- 
ignated A(E2), B(E2), and C(E2) were de- 
fined on the E2 glycoprotein by four neu- 
tralizing antibodies. Sites B(E2) and C(E2) 
were identified by the binding of 5813.5 
and 4B11.6, respectively. Two antibodies, 
5B19.2 and 5B170.3, were both directed to 
site A(E2). Each competing pair was ex- 
amined by reciprocal competition assays 
with both members in a combination con- 
jugated in turn to minimize the effect of 
differing avidity (Stone and Nowinski, 
1980). These results presented an inter- 
esting paradox. Antibody 4B11.6 directed 
against site C(E2) neutralized virus effi- 
ciently in vitro but failed in other studies 
to protect mice against a lethal virus chal- 
il"HAP-581i0.3 bEi 6'1 
pg lmmunoglobulin 
FIG. 5. Competition binding EIA with HRP-con- 
jugated monoclonal antibodies directed against gly- 
coprotein E2. Assays were done as described in the 
legend for Fig. 4. Enzyme-conjugated antibodies di- 
rected against E2 were l ,5B19.2 (A); V, 5B170.3 (B), 
A, 5A13.5 (C); and n , 4B11.6 (D). 
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TABLE 2 
SUMMARY OF COMPETITION BINDING ENZYME IMMUNOASSAYS BETWEEN MONOCLONAL ANTIBODIES TO MHV-4” 
Enzyme-conjugated probe 
Nonconjugated E2 Antibodies El Antibodies 
competing 
antibody 5B19.2 5B170.3 5A13.5 4B11.6 5B119.4 5A5.2 5B128.3 
E2 antibodies 
5B19.2 0 0 0 0 0 0 0 
5B170.3 0 0 0 0 0 0 0 
5813.5 0 0 0 0 0 0 0 
4B11.6 0 0 0 0 0 0 0 
El antibodies 
5B11.5 0 0 0 0 a 0 0 
5B119.4 0 0 0 0 0 0 0 
545.2 0 0 0 0 0 0 0 
5B128.3 0 0 0 0 0 0 a 
Note. Summary of data presented in Figs. 4 and 5. 
a Percentage of homologous blocking at 1 pg immunoglobulin. 0, >80%; Or 35-701; 0, <30%. 
lenge in wivo (Buchmeier et d, 1984), 
whereas three other neutralizing antihod- 
ies, 5B19.2, 5B170.3, and 5A13.5, were pro- 
tective in wivo. These MAb were directed 
to two topographically distinct antigenic 
sites designated A(E2) and B(E2). This in- 
dicates the presence on E2 of multiple to- 
pographically distinct regions associated 
with virus attachment on the host cell. 
Preliminary studies indicate that antigenic 
variation at sites B(E2) and C(E2) can be 
detected in various MHV strains (Talbot 
and Buchmeier, unpublished, 1984). These 
two antigenic sites may be conformation- 
dependent determinants since their reac- 
tivity is lost after SDS denaturation and 
Western immunoblotting (Table 1). We 
have made the assumption that antigenic 
sites A, B, and C(E2), all of which give rise 
to neutralizing antibodies, are freely ac- 
cessible to the external milieu. 
Four nonneutralizing E2 antibodies were 
shown by solid-phase EIA to bind to the 
viral protein, at a distinct site or sites des- 
ignated D(E2) since they did not affect an- 
tibody binding to antigenic sites A, B, or 
C(E2). More definitive characterization 
awaits development of reliable conjugates 
of these antibodies. Binding curves for 
these nonneutralizing antibodies were 
similar to those of the neutralizing anti- 
bodies suggesting that failure to neutralize 
was not due to gross differences in titer or 
binding avidity. Nonneutralizing antibod- 
ies to viral attachment proteins have now 
been demonstrated for the retroviruses 
(Massey and Schochetman, 1981; Bruck et 
ak, 1982), togaviruses (Roehrig et a& 1980; 
Kimura-Kuroda and Yasui, 1983), ortho- 
myxoviruses (Breschkin et al, 1981; Carter 
et d, 1982), rhabdoviruses (Volk et aL, 
1982), and reoviruses (Burstin et &, 1982). 
We found that antibodies to El or E2 which 
failed to neutralize in vitro also did not 
alter the disease process in tivo (Buch- 
meier et al, 1984), in contrast to nonneu- 
tralizing MAb to Sindbis virus which pre- 
vented lethal encephalitis in viva (Schmal- 
john et uk, 1982). 
Glycoprotein El contained at least three 
epitopes, designated A(El), B(El), and 
C(El), defined by five MAb. These epitopes 
could be grouped into two nonoverlapping 
antigenic sites, as defined by Yewdell and 
Gerhard (1981). These antibodies appear 
to recognize the apoprotein of El since they 
bound well to both the 23K nonglycosylated 
precursor and the 25K glycosylated form. 
Site C(E1) was clearly distinct and rec- 
ognized only by antibody 5B128.3. Defini- 
tion of possibly overlapping epitopes A(E1) 
and B(E1) by antibodies 5B119.4,5A5.2, and 
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5B11.5 is less certain. Binding of these an- 
tibodies was only partially cross-inhibited 
and this may be due to steric hindrance 
rather than site specific competition as El 
is small (25K) relative to the IgG peroxi- 
dase probe (200K). Antibody 5B39.1 was 
shown to bind to the viral protein but did 
not affect the binding of the other anti- 
bodies. Its target epitope is thus likely dis- 
tinct from epitopes A and B and C(El), 
although the absence of a reliable enzyme 
conjugate of 5B39.1 did not allow its de- 
finitive topographical assignment. 
Our studies further confirm the presence 
in infected cells of an approximately 150K 
precursor to the structural glycoprotein E2 
(Wege et d, 1979; Siddell et aL, 1981). 
Monoclonal antibodies to E2 also recog- 
nized a 1OOK monomer and high M, poly- 
peptides as reported previously (Wege et 
aL, 1979; Siddell et al, 1981; Sturman and 
Holmes, 1983). 
Studies of others on detergent-solubi- 
lized virions as well as the observation that 
approximately 80% of the El protein is 
protected from protease digestion have 
implied that El is a transmembranous 
protein interacting inside the virion with 
the nucleocapsid and may organize sites of 
virus maturation in the cell (Sturman and 
Holmes, 1977; Wege et al, 1979; Sturman 
et aL, 1980; Holmes et ah, 1981). In contrast, 
E2 was completely digested by protease 
treatment and did not appear to be nec- 
essary for virus maturation since virus 
particles formed in the presence of tuni- 
camycin lacked E2 peplomers (Holmes et 
uL, 1981). Recently, E2 was shown to 
contain covalently attached fatty acid 
(Schmidt, 1982), which is the only indi- 
cation that a portion of this glycoprotein 
might be exposed to a hydrophobic envi- 
ronment. Therefore, current knowledge of 
MHV structure is consistent with the hy- 
pothesis that El may serve to anchor the 
E2 peplomers within the viral envelope 
(Sturman et aL, 1980). The apparent stoie- 
chiometric excess of El over E2 proteins 
(Sturman et d, 1980, Sturman and Holmes, 
1983) would be explained if several El mol- 
ecules formed a complex around an E2 
stalk peripherally embedded in the mem- 
brane. This association would allow E2 to 
form hydrophobic domains by interaction 
with this El anchor. However, we have 
failed so far to obtain MAb directed against 
epitopes on the two viral glycoproteins 
which would be in close enough proximity 
to cause mutual steric hindrance in com- 
petition binding EIA. Our membrane-en- 
riched antigen source presumably contains 
both plasma membranes and microsomal 
membranes thus obviating any speculation 
about the localization of the viral glyco- 
proteins in this system. All competition 
binding EIA were consistent in the pres- 
ence or absence of the nonionic detergent 
Tween 20 in the assay buffers. This elim- 
inates the possibility of structural reor- 
ganizations induced by the detergent. Ob- 
viously, more precise structural studies are 
needed to define the molecular arrange- 
ment of these proteins. 
Monoclonal antibodies have proven to be 
sensitive probes to study the biology and 
structure of MHV-4 and we have used them 
to characterize biologically important an- 
tigenic regions of the viral glycoproteins. 
Studies are currently underway in our lab- 
oratory to examine the structural prop- 
erties of these glycoproteins with the goal 
of better understanding the molecular ba- 
sis of virus-induced demyelination. 
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